Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion

S. Chiara, M. T. Nobile, C. Barzacchi, O. Sanguineti, M. Vincenti, C. Di Somma, P. Meszaros, R. Rosso

Research output: Contribution to journalArticlepeer-review


The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy. 70 advanced colorectal cancer patients (pts) were given weekly 24 h continuous 5-FU (2600 mg/m2) infusion plus L- LV (100 mg/m2 i.v., 50 mg orally). The toxicity, in particular HFS, was analysed, correlated to the main pts characteristics and compared to the other observed side-effects. HFS occurred in 36/70 pts (51%): grade 1 in 16 pts, grade 2 in 16 pts, grade 3 in 3 pts and grade 4 in 1 pt. It occurred after a median number of nine courses. In one case, chemotherapy was interrupted for this toxicity, and in another 5 pts drug reduction and/or treatment delay were undertaken. Changes in the therapeutic programme because of diarrhoea or mucositis were more frequent, even though these toxicities were generally mild in our series of pts. HFS was significantly correlated to previous exposure to chemotherapy (P= 0.00003). HFS was a frequent side-effect of high-dose, short-term continuous 5-FU infusion, but the impact on quality of life of pts and on the correct delivery of the planned chemotherapy was limited.

Original languageEnglish
Pages (from-to)967-969
Number of pages3
JournalEuropean Journal of Cancer
Issue number6
Publication statusPublished - May 1997


  • 5-fluorouracil
  • Colorectal cancer
  • Continuous infusion
  • Hand-foot syndrome

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion'. Together they form a unique fingerprint.

Cite this